LivaNova PLC (LIVN) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $59.02 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 6 days (event risk); Weak growth.
LivaNova is a global medical technology company with two segments: Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion systems) and Neuromodulation (VNS Therapy for drug-resistant epilepsy and treatment-resistant depression). Revenue comes from device sales and... Read more
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $59.02 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 6 days (event risk); Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMSuppliersingle supplier10-K Item 1A: 'in some cases, LivaNova purchases specific components and raw materials from primary or main suppliers (or in some cases, a single supplier)'
- MEDIUMGeographicItaly and Germany10-K Item 1A: 'A significant number of LivaNova's Cardiopulmonary products and component parts are sourced and produced outside of the U.S., including in Italy and Germany.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $59.02 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 6 days (event risk); Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $56.39. Score 5.1/10, moderate confidence.
Take-profit target: $68.89 (+16.7% upside). Prior stop was $56.39. Stop-loss: $56.39.
Earnings in 6 days (event risk); Weak growth; Negative momentum.
LivaNova PLC trades at a P/E of N/A (forward 12.9). TrendMatrix value score: 7.7/10. Verdict: Sell.
17 analysts cover LIVN with a consensus score of 4.1/5. Average price target: $79.
What does LivaNova PLC do?LivaNova is a global medical technology company with two segments: Cardiopulmonary (heart-lung machines, oxygenators,...
LivaNova is a global medical technology company with two segments: Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion systems) and Neuromodulation (VNS Therapy for drug-resistant epilepsy and treatment-resistant depression). Revenue comes from device sales and services to hospitals and medical professionals globally. The company is headquartered in London and listed on Nasdaq under LIVN.